TRPC6 and acute respiratory distress syndrome: A recent clinical study by the pharmaceutical company Boehringer-Ingelheim with another TRPC6 antagonists (BI 764198) in prevention/progression of ARDS and ARDS-related complications secondary to COVID-19 (see https://clinicaltrials.gov under NCT04604184, accessed date: 14 September 2022) was, however, interrupted in 2022 due to lack of efficiency (https://www.boehringer-ingelheim.de/covid-19/kampf-gegen-covid-19/forschungsupdate, accessed date: 14 September 2022).